Skip to main content
. 2004 Oct 5;101(Suppl 2):14657–14662. doi: 10.1073/pnas.0404866101

Fig. 1.

Fig. 1.

Aβ42-immunized TgCRND8 mice have a 50% reduction in plaque burden than untreated TgCRND8 mice. Representative pictures of the distribution of Aβ plaques labeled by Dako 6F/3D anti-Aβ antibody in the hippocampus (A and B) and cortex (C and D) of control peptide-immunized (A and C) and Aβ42-immunized TgCRND8 mice (B and D). (Scale bars = 100 μm.)